Caption Management Adds $19M in COMPASS Pathways plc ($CMPS)
Key Points
- Wall Street's consensus rating on $CMPS is Strong Buy and an average price target of $22.20.
- $CMPS last traded around $12.08.
Caption Management acquired a new position in COMPASS Pathways plc ($CMPS), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,610,130 shares of COMPASS Pathways plc. Caption Management's holdings in COMPASS Pathways plc were worth $19.45 million as of its most recent filing.
COMPASS Pathways plc ($CMPS) Stock
COMPASS Pathways plc Earnings
Analysts Set New Price Targets
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.